HZNP - possible long play
Horizon Pharma HZNP – belongs to the medical industry.
Shares of HZNP jumped 36.7% this year compared to the decline of 1.9% of the sector.
HZNP has recently been working on expanding its marketed pharmaceuticals - Procisbee, Actimona and Revicetti, in addition, in July of this year the company announced the FDA's acceptance of its new drug application.
Level 28 seems to be resistance level, there have been several attempts to break the level since the beginning of August.
Reference points:
o RSI indicator is not yet in over-buying area
o The OBV indicator supports the proposed direction
o Strengthening of trading volume must be followed
Follow-up for a possible entry above 28 level, after an approval candle and support of the market movement.
All of the above, of course, at your discretion, your accepted trading rules, trading strategies and your preferred trading management.
This is not a recommendation to buy or sell.
Shares of HZNP jumped 36.7% this year compared to the decline of 1.9% of the sector.
HZNP has recently been working on expanding its marketed pharmaceuticals - Procisbee, Actimona and Revicetti, in addition, in July of this year the company announced the FDA's acceptance of its new drug application.
Level 28 seems to be resistance level, there have been several attempts to break the level since the beginning of August.
Reference points:
o RSI indicator is not yet in over-buying area
o The OBV indicator supports the proposed direction
o Strengthening of trading volume must be followed
Follow-up for a possible entry above 28 level, after an approval candle and support of the market movement.
All of the above, of course, at your discretion, your accepted trading rules, trading strategies and your preferred trading management.
This is not a recommendation to buy or sell.
,The quieter you become
the more you can hear
(Ram Dass)
the more you can hear
(Ram Dass)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.